271 related articles for article (PubMed ID: 38007239)
21. PTK7-Targeting CAR T-Cells for the Treatment of Lung Cancer and Other Malignancies.
Jie Y; Liu G; Feng L; Li Y; E M; Wu L; Li Y; Rong G; Li Y; Wei H; Gu A
Front Immunol; 2021; 12():665970. PubMed ID: 34475869
[TBL] [Abstract][Full Text] [Related]
22. [Efficacy and safety of CD19 chimeric antigen receptor T cells for the treatment of 22 patients with B-cell lymphoma].
Xiao X; Jiang YY; Cao YQ; Li Q; Jin X; Meng JX; Sui T; Li YM; Zhao MF
Zhonghua Xue Ye Xue Za Zhi; 2019 Apr; 40(4):276-280. PubMed ID: 31104437
[No Abstract] [Full Text] [Related]
23. Translational development of a novel BAFF-R CAR-T therapy targeting B-cell lymphoid malignancies.
Luo Y; Qie Y; Gadd ME; Manna A; Rivera-Valentin R; To T; Li S; Yassine F; Murthy HS; Dronca R; Kharfan-Dabaja MA; Qin H
Cancer Immunol Immunother; 2023 Dec; 72(12):4031-4047. PubMed ID: 37814001
[TBL] [Abstract][Full Text] [Related]
24. CAR T Cells with Enhanced Sensitivity to B Cell Maturation Antigen for the Targeting of B Cell Non-Hodgkin's Lymphoma and Multiple Myeloma.
Bluhm J; Kieback E; Marino SF; Oden F; Westermann J; Chmielewski M; Abken H; Uckert W; Höpken UE; Rehm A
Mol Ther; 2018 Aug; 26(8):1906-1920. PubMed ID: 30078440
[TBL] [Abstract][Full Text] [Related]
25. Efficacy and toxicity for CD22/CD19 chimeric antigen receptor T-cell therapy in patients with relapsed/refractory aggressive B-cell lymphoma involving the gastrointestinal tract.
Zeng C; Cheng J; Li T; Huang J; Li C; Jiang L; Wang J; Chen L; Mao X; Zhu L; Lou Y; Zhou J; Zhou X
Cytotherapy; 2020 Mar; 22(3):166-171. PubMed ID: 32063474
[TBL] [Abstract][Full Text] [Related]
26. Compromised antigen binding and signaling interfere with bispecific CD19 and CD79a chimeric antigen receptor function.
Leung I; Templeton ML; Lo Y; Rajan A; Stull SM; Garrison SM; Salter AI; Smythe KS; Correnti CE; Srivastava S; Yeung CCS; Riddell SR
Blood Adv; 2023 Jun; 7(12):2718-2730. PubMed ID: 36469024
[TBL] [Abstract][Full Text] [Related]
27. [Effect of Special Structure Bi-Specific Chimeric Antigen Receptor T Cell on Tumor Cells].
Liu C; Peng H; Zeng WJ; Li W; Chen KK; Li WT; Zeng GF; Liang X; Hu JY; Zhou M
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2022 Dec; 30(6):1730-1740. PubMed ID: 36476896
[TBL] [Abstract][Full Text] [Related]
28. Multispecific CAR T Cells Deprive Lymphomas of Escape via Antigen Loss.
Furqan F; Shah NN
Annu Rev Med; 2023 Jan; 74():279-291. PubMed ID: 36332638
[TBL] [Abstract][Full Text] [Related]
29. Chimeric Antigen Receptor T-Cell Therapies for Aggressive B-Cell Lymphomas: Current and Future State of the Art.
Abramson JS; Lunning M; Palomba ML
Am Soc Clin Oncol Educ Book; 2019 Jan; 39():446-453. PubMed ID: 31099671
[TBL] [Abstract][Full Text] [Related]
30. T-cells engineered with a novel VHH-based chimeric antigen receptor against CD19 exhibit comparable tumoricidal efficacy to their FMC63-based counterparts.
Nasiri F; Safarzadeh Kozani P; Rahbarizadeh F
Front Immunol; 2023; 14():1063838. PubMed ID: 36875091
[TBL] [Abstract][Full Text] [Related]
31. Anti-CD37 chimeric antigen receptor T cells are active against B- and T-cell lymphomas.
Scarfò I; Ormhøj M; Frigault MJ; Castano AP; Lorrey S; Bouffard AA; van Scoyk A; Rodig SJ; Shay AJ; Aster JC; Preffer FI; Weinstock DM; Maus MV
Blood; 2018 Oct; 132(14):1495-1506. PubMed ID: 30089630
[TBL] [Abstract][Full Text] [Related]
32. Anti-CD19 CAR T-Cell Therapy for B-Cell Non-Hodgkin Lymphoma.
Abramson JS
Transfus Med Rev; 2020 Jan; 34(1):29-33. PubMed ID: 31677848
[TBL] [Abstract][Full Text] [Related]
33. Humanized CD19 CAR-T cells in relapsed/refractory B-ALL patients who relapsed after or failed murine CD19 CAR-T therapy.
An L; Lin Y; Deng B; Yin Z; Zhao D; Ling Z; Wu T; Zhao Y; Chang AH; Tong C; Liu S
BMC Cancer; 2022 Apr; 22(1):393. PubMed ID: 35410148
[TBL] [Abstract][Full Text] [Related]
34. Construction and functional characterization of a fully human anti-CD19 chimeric antigen receptor (huCAR)-expressing primary human T cells.
Mirzaei HR; Jamali A; Jafarzadeh L; Masoumi E; Alishah K; Fallah Mehrjardi K; Emami SAH; Noorbakhsh F; Till BG; Hadjati J
J Cell Physiol; 2019 Jun; 234(6):9207-9215. PubMed ID: 30362586
[TBL] [Abstract][Full Text] [Related]
35. A novel chimeric antigen receptor containing a JAK-STAT signaling domain mediates superior antitumor effects.
Kagoya Y; Tanaka S; Guo T; Anczurowski M; Wang CH; Saso K; Butler MO; Minden MD; Hirano N
Nat Med; 2018 Mar; 24(3):352-359. PubMed ID: 29400710
[TBL] [Abstract][Full Text] [Related]
36. A safe and potent anti-CD19 CAR T cell therapy.
Ying Z; Huang XF; Xiang X; Liu Y; Kang X; Song Y; Guo X; Liu H; Ding N; Zhang T; Duan P; Lin Y; Zheng W; Wang X; Lin N; Tu M; Xie Y; Zhang C; Liu W; Deng L; Gao S; Ping L; Wang X; Zhou N; Zhang J; Wang Y; Lin S; Mamuti M; Yu X; Fang L; Wang S; Song H; Wang G; Jones L; Zhu J; Chen SY
Nat Med; 2019 Jun; 25(6):947-953. PubMed ID: 31011207
[TBL] [Abstract][Full Text] [Related]
37. Bispecific anti-CD20, anti-CD19 CAR T cells for relapsed B cell malignancies: a phase 1 dose escalation and expansion trial.
Shah NN; Johnson BD; Schneider D; Zhu F; Szabo A; Keever-Taylor CA; Krueger W; Worden AA; Kadan MJ; Yim S; Cunningham A; Hamadani M; Fenske TS; Dropulić B; Orentas R; Hari P
Nat Med; 2020 Oct; 26(10):1569-1575. PubMed ID: 33020647
[TBL] [Abstract][Full Text] [Related]
38. CD19/CD22 Dual-Targeted CAR T-cell Therapy for Relapsed/Refractory Aggressive B-cell Lymphoma: A Safety and Efficacy Study.
Wei G; Zhang Y; Zhao H; Wang Y; Liu Y; Liang B; Wang X; Xu H; Cui J; Wu W; Zhao K; Nagler A; Chang AH; Hu Y; Huang H
Cancer Immunol Res; 2021 Sep; 9(9):1061-1070. PubMed ID: 34290048
[TBL] [Abstract][Full Text] [Related]
39. Lym-1 Chimeric Antigen Receptor T Cells Exhibit Potent Anti-Tumor Effects against B-Cell Lymphoma.
Zheng L; Hu P; Wolfe B; Gonsalves C; Ren L; Khawli LA; Kaslow HR; Epstein AL
Int J Mol Sci; 2017 Dec; 18(12):. PubMed ID: 29261129
[TBL] [Abstract][Full Text] [Related]
40. Adoptive transfer of syngeneic T cells transduced with a chimeric antigen receptor that recognizes murine CD19 can eradicate lymphoma and normal B cells.
Kochenderfer JN; Yu Z; Frasheri D; Restifo NP; Rosenberg SA
Blood; 2010 Nov; 116(19):3875-86. PubMed ID: 20631379
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]